The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.

@article{Ebner1993TheMO,
  title={The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.},
  author={Thomas Ebner and Michel F Eichelbaum},
  journal={British journal of clinical pharmacology},
  year={1993},
  volume={35 4},
  pages={
          426-30
        }
}
1. Incubation of the class I antiarrhythmic drug aprindine (AP) with human liver microsomes resulted in the formation of two hydroxylated metabolites (HA1 and HA2) and desethylaprindine which were identified by GC-mass spectrometry. In liver microsomes isolated from a poor metaboliser (PM) of sparteine no hydroxylated metabolites of AP were detected whereas AP N-dealkylation was unimpaired. Thus hydroxylation of AP is mediated by cytochrome P450 2D6 (CYP2D6). 2. AP was found to be a competitive… 

Figures and Tables from this paper

Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance
TLDR
There is a considerable variability in the CYP2D6 allele distribution among different ethnic groups, resulting in variable percentages of PMs, IMs, EMs and UMs in a given population and the number of alleles is still growing.
Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications
TLDR
A comparative evaluation on the ability of four commonly used in silico tools to correctly predict the CYP2D6-derived site of metabolism (SOM) for 141 compounds, including 10 derived from the Genentech small molecule library.
Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.
TLDR
It is concluded that genetic polymorphisms of biotransformation enzymes are in a number of cases a major factor involved in the interindividual variability in xenobiotic metabolism and toxicity.
Polymorphism of human cytochrome P450 enzymes and its clinical impact
TLDR
Current pharmacogenetic knowledge on important human drug-metabolizing cytochrome P450s (CYPs) is highlighted to understand the large interindividual variability in drug clearance and responses in clinical practice and to improve the efficacy and safety of both prospective and currently available drugs.
Drug Interaction between Diltiazem and Aprindine. II
TLDR
The results suggested that the mechanism of interaction between DTZ and AP is competitive inhibition and it is dependent on intestinal CYP3A.
Interaction between Diltiazem and Antiarrhythmic Drugs
TLDR
The pharmacokinetic interactions of diltiazem and the antiarrhythmic drugs aprindine and mexiletine were studied in beagle dogs and in patients with arrhythmia, demonstrating the existence of such an interaction.
Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates
TLDR
A structure-based outline of CYP-catalyzed biotransformations of selected substrates, representing diverse structural classes of chemicals, ranging from drugs to toxicants is presented.
Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine
TLDR
Genotypes are key determinants of interindividual variability in CYP2D6 expression and activity and post-translational modifications such as phosphorylation of CYP 2D6 Ser135 have been observed, but the functional impact is unknown.
...
1
2
3
...

References

SHOWING 1-10 OF 35 REFERENCES
Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitro.
TLDR
The different ratio of these two dehydrosparteines, which was found at low and high substrate concentrations, suggests that the reactions producing the primary metabolite are different between the quinidine-sensitive and -insensitive enzymes.
In vitro characterization of the human cytochrome P‐450 involved in polymorphic oxidation of propafenone
TLDR
5‐hydroxypropafenone is formed by the cytochrome P‐450 isozyme involved in polymorphic bufuralol oxidation, and was a strong competitive inhibitor ofbufuralol l'hydroxylation.
Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
TLDR
This study demonstrates the efficiency of the PCR-test for phenotype prediction; 96.4% of individuals were correctly predicted, i.e., 100% of the extensive metabolizers (EMs) and 86.0%" of the poor metabolizer phenotype (PMs).
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations
Interethnic differences in debrisoquin and mephenytoin hydroxylation have been compared between normal white (n = 183) and Japanese (n = 100) subjects with the 8‐hour urinary metaboUc ratio of
Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism.
TLDR
The enantiomers of propafenone interact with respect to 5-hydroxylation, with (R)-propafen one being a more potent inhibitor than the S-enantiomer with respectto cytochrome P450IID6-mediated 5-Hydroxylations.
A nuclear magnetic resonance study of sparteine delta metabolite structure.
TLDR
The metabolism of (-)-sparteine was reinvestigated by high-resolution 1H, 2H, and 13C-NMR spectroscopy, and reversed-phase TLC likewise confirms the different structural principle of the two main sparteine metabolites.
...
1
2
3
4
...